EYPT Stock Analysis: Buy, Sell, or Hold?
EYPT - EyePoint Pharmaceuticals, Inc. Common Stock
$12.35
-0.89 (-6.72%)
▼
5d:
-9.59%
30d:
-16.61%
90d:
-4.56%
SELL
MODERATE Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 06, 2026
0d
Smart Money Accumulation
EYPT is down 9.6% this week, but smart money is accumulating calls. Top strike: $15 2026-06-18 with 251 OI. Call ratio: 64% View Scanner →
Strength: 6.2/10
Get Alerted When EYPT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⚠️ CAUTION: EYPT is extended with warning signals. Consider taking profits or waiting for better entry.
⚠️ CAUTION: EYPT is extended with warning signals. Consider taking profits or waiting for better entry.
In-depth Analysis How we analyze
Valuation Analysis: EYPT is currently trading at $12.35, which is considered extended relative to its 30-day fair value range of $13.35 to $14.50.
Technical Outlook: Technically, EYPT is in a downtrend. The price is currently testing key support at $12.64. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.7% recently.
Market Sentiment: EYPT has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $37.17 (+200.9%). Given the valuation headwinds and technical position, caution is warranted at these levels.
Technical Outlook: Technically, EYPT is in a downtrend. The price is currently testing key support at $12.64. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.7% recently.
Market Sentiment: EYPT has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $37.17 (+200.9%). Given the valuation headwinds and technical position, caution is warranted at these levels.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$13.35 -
$14.50
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
21.1%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.7%)
- BULLISH: Trading 200.9% below Wall St target ($37.17)
Trading Range Analysis
30-Day Trading Range
$13.35 -
$14.50
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$12.64
Resistance Level
$14.68
Current Trend
Downtrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.35
Wall Street Target
$37.17
(+200.9%)
Revenue Growth (YoY)
161.7%
Share & Embed Analysis
Last updated: May 18, 2026 9:44 AM ET
Data refreshes hourly during market hours. Next update: 10:44 AM
Data refreshes hourly during market hours. Next update: 10:44 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EYPT showing a specific setup today?
Insider Activity (6 Months)
1
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Ramiro Ribeiro
SELL
2437 shares
2026-04-17
Jay S Duker
BUY
1500 shares
2026-03-16
Ramiro Ribeiro
SELL
42544 shares
2026-01-05
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$90 | 60 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 62 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 59 HOLD |
|
BHVN
Biohaven Pharmaceutical … |
STRONG BUY
16 analysts |
$22 | 57 HOLD |
|
RVMD
Revolution Medicines Inc |
STRONG BUY
12 analysts |
$181 | 61 BUY |
